Bladder microbiome and BCG therapy response in cancer
Shotgun metagenomic study of 163 samples from Vancouver and Cleveland, associating the bladder microbiome with response to BCG therapy for bladder cancer and with cancer recurrence. machine-written summary
163 samples · 163 runs · CA, US · Age unknown · 2026 · 3.89 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,367 sample values (collection date, country, health condition, health condition detail, intervention, intervention detail, latitude, location locality) |
| – Abstract / description | no abstract or project description |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
design observational_with_procedure
longitudinal — not resolved
17 of 32 people sampled more than once (34 samples; median 2, up to 2 per person). Schedule stated by the source: “Samples collected before and after BCG therapy, at cystoscopy visits (e.g. Cysto11) and BCG treatment timepoints (BCG, BCG1); stool and urine per visit.”.
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 163 | 100% | 163 | |||
| health_condition | 97 | 60% | 97 | |||
| subject_id | 163 | 100% | 163 | |||
| timepoint_label | 150 | 92% | 150 | |||
| health_condition_detail | 141 | 87% | 141 | |||
| detailed_location | 80 | 49% | ||||
| latitude | 80 | 49% | 80 | |||
| location_locality | 80 | 49% | 80 | |||
| longitude | 80 | 49% | 80 | |||
| intervention | 78 | 48% | 78 | |||
| intervention_detail | 78 | 48% | 78 | |||
| location_region | 77 | 47% | 77 | |||
| sex | 75 | 46% | 75 | |||
| smoking_status | 74 | 45% | 74 | |||
| collection_date | 31 | 19% | 31 |
Archive description
Using shotgun metagenomic data, this project sought to associate the bladder microbiome to the response to BCG therapy for bladder cancer, along with cancer recurrence.
How this project entered the registry
Classified as human vaginal / urogenital / gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.60. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site study.title · “Impact of bladder microbiome on BCG response”
- body site sample.attr.env_local_scale · “stool (n=42/163)”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN56287171 | collection_date | 2022-09-21 | R1 | 0.90 | biosample.attribute:collection_date | 2022-09-21 |
| SAMN56287121 | country | US | R1 | 0.90 | sample.attr.geo_loc_name | USA: Cleveland |
| SAMN56287123 | health_condition | other_disease | R1 | 0.60 | biosample_attr | Yes |
| SAMN56287121 | health_condition_detail | No | R1 | 0.90 | sample.attr.host_disease | No |
| SAMN56287121 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:Timepoint | Timepoint: Before |
| SAMN61845440 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:treatment_timepoint | treatment_timepoint: negative control |
| SAMN56287121 | intervention_detail | baseline sample before BCG therapy | R1 | 0.90 | biosample.attribute:Timepoint | Timepoint: Before |
| SAMN61845440 | intervention_detail | control arm, no BCG therapy | R1 | 0.90 | biosample.attribute:treatment_timepoint | treatment_timepoint: negative control |
| SAMN56287121 | latitude | 41.5000 | R1 | 0.90 | biosample.attribute:lat_lon | 41.50 N 81.69 W |
| SAMN56287121 | location_locality | Cleveland | R1 | 0.85 | biosample.attribute:geo_loc_name | USA: Cleveland |
| SAMN56287125 | location_region | British Columbia | R1 | 0.60 | biosample.attribute:lat_lon | 49.28 N 123.12 W |
| SAMN56287121 | longitude | -81.6900 | R1 | 0.90 | biosample.attribute:lat_lon | 41.50 N 81.69 W |
| SAMN61845448 | sex | male | R1 | 0.90 | sample.attr.host_sex | male |
| SAMN61845448 | smoking_status | never | R1 | 0.80 | biosample.attribute:smoker | no |
| SAMN56287121 | subject_id | RH005 | R1 | 0.85 | sample.attr.host_subject_id | RH005 |
| SAMN56287121 | timepoint_label | Before | R1 | 0.85 | sample.attr.timepoint | Before |
| SAMN61845440 | timepoint_label | negative control | R1 | 0.85 | biosample.attribute:treatment_timepoint | treatment_timepoint: negative control |
Sequencing
163 runs over 163 samples · mean 4.15 Gbp per run (median 3.89 Gbp, total 676.99 Gbp; 163 runs with a base count) · layout PAIRED 163 · platform ILLUMINA 163 · models Illumina NovaSeq X Plus (83), Illumina NovaSeq X (80) · 0% of runs with a Sandpiper profile · first public 2026-05-06 – 2026-07-26
Authors (0)
No author record.
Downloads
PRJNA1430386.csv.gz (5.9 KB) · parquet (79.0 KB) — all 163 samples, every field with route and confidence · PRJNA1430386_determinations.csv.gz (10.1 KB) — 1,367 evidence rows